Logo

Aviva Licenses Regulatory Gene-Mapping Tech from UCSD

Feb 01, 2005

NEW YORK, Feb. 1 (GenomeWeb News) - Aviva Systems Biology has licensed the rights to develop and commercialize products based on Gene Regulation Elements Mapping and Analysis (GREMA) technology from the University of California, San Diego, the company said today.

 

GREMA, developed by UCSD professor of cellular and molecular biology Xiangdong Fu, is a method for detecting DNA fragments, such as promoters, that interact with proteins, Aviva said.

 

Aviva has used its bioinformatics platform to identify approximately 32,000 potential promoter sequences, 20,000 of which it has incorporated into a DNA microarray to be sold to the basic research market.

 

According to a company representative, Aviva has essentially developed the chip, and hopes to launch the product in about two months.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.